CSIMarket
 


Corcept Therapeutics Inc  (CORT)
Other Ticker:  
 
 

CORT's Revenue Growth by Quarter and Year

Corcept Therapeutics Inc's Revenue results by quarter and year




CORT Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 135.41 103.06 98.82 85.74
III Quarter September 123.60 101.73 96.13 86.33
II Quarter June 117.72 103.39 91.59 88.57
I Quarter March 105.65 93.69 79.44 93.25
FY   482.38 401.87 365.98 353.89



CORT Revenue fourth quarter 2023 Y/Y Growth Comment
Corcept Therapeutics Inc reported Revenue improvement of 31.38% year on year in the fourth quarter 2023, to $ 135.41 millions, this is lower than Corcept Therapeutics Inc's recent average Revenue rise of 58.76%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Revenue growth. While Corcept Therapeutics Inc' s Revenue rise of 31.38% ranks overall at the positon no. 362 in the fourth quarter 2023.




CORT Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 31.38 % 4.29 % 15.26 % -2.46 %
III Quarter September 21.5 % 5.83 % 11.35 % 5.91 %
II Quarter June 13.86 % 12.88 % 3.41 % 22.57 %
I Quarter March 12.77 % 17.94 % -14.81 % 43.84 %
FY   20.03 % 9.81 % 3.42 % 15.46 %

Financial Statements
Corcept Therapeutics Inc's fourth quarter 2023 Revenue $ 135.41 millions CORT's Income Statement
Corcept Therapeutics Inc's fourth quarter 2022 Revenue $ 103.06 millions Quarterly CORT's Income Statement
New: More CORT's historic Revenue Growth >>


CORT Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 9.55 % 1.31 % 2.8 % -0.68 %
III Quarter September 4.99 % -1.61 % 4.96 % -2.53 %
II Quarter June 11.42 % 10.35 % 15.29 % -5.02 %
I Quarter March 2.51 % -5.19 % -7.35 % 6.09 %
FY (Year on Year)   20.03 % 9.81 % 3.42 % 15.46 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #33
Overall #362

Revenue Y/Y Growth Statistics
High Average Low
184.2 % 58.76 % -2.31 %
(Sep. 30, 2014)   (Jun 30 2021)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #33
Overall #362
Revenue Y/Y Growth Statistics
High Average Low
184.2 % 58.76 % -2.31 %
(Sep. 30, 2014)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Corcept Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56.23 % 12.23 % -7.35 %
(Dec 31 2013)  


CORT's IV. Quarter Q/Q Revenue Comment
Corcept Therapeutics Inc achieved in the IV. Quarter 2023 below company average Revenue increase of 9.55% quarter on quarter, to $ 135.41 millions.

IV. Quarter 2023 Corcept Therapeutics Inc's performance appear to be paradoxical, although beneath the ordinary, yet it demonstrates a quite recovery relative to the 1.31% in the same quarter a year ago Vihaan Sengupta , an industry advisor located in New York said.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Corcept Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 141.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #12
Overall #141
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #12
Overall #141
Revenue Q/Q Growth Statistics
High Average Low
56.23 % 12.23 % -7.35 %
(Dec 31 2013)  


CORT's IV. Quarter Q/Q Revenue Comment
Corcept Therapeutics Inc achieved in the IV. Quarter 2023 below company average Revenue increase of 9.55% quarter on quarter, to $ 135.41 millions.

IV. Quarter 2023 Corcept Therapeutics Inc's Revenue sequential growth appear to be contradictory, albeit beneath the regular increase of 12.23 %, yet it presents absolute recovery compare to the 1.31% in the IV. Quarter 2022 Vihaan Sengupta , an industry advisor located in New York said.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Corcept Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 141.


Corcept Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 482.38 $ 450.03 $ 428.15 $ 413.82 $ 401.86
Y / Y Revenue Growth (TTM) 20.04 % 13.18 % 9.22 % 8.84 % 9.8 %
Year on Year Revenue Growth Overall Ranking # 201 # 1095 # 325 # 461 # 1660
Seqeuential Revenue Change (TTM) 7.19 % 5.11 % 3.46 % 2.98 % 1.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 362 # 870 # 661 # 2262 # 1642




Cumulative Revenue growth Comment
Although Corcept Therapeutics Inc's Annual Revenue growth year on year were below company's average 58.76% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.04% year on year, from 13.18% in Sep 30 2023.

Among companies within the Healthcare sector 18 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 201, from total ranking in previous quarter at 1095.

Revenue TTM Q/Q Growth Statistics
High Average Low
184.2 %
58.76 %
-2.31 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 19
Overall # 201

Revenue TTM Y/Y Growth Statistics
High Average Low
184.2 %
58.76 %
-2.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 33
S&P 500 # 362
Cumulative Revenue growth Comment
Although Corcept Therapeutics Inc's Annual Revenue growth year on year were below company's average 58.76% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.04% year on year, from 13.18% in Sep 30 2023.

Among companies within the Healthcare sector 18 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 201, from total ranking in previous quarter at 1095.

Revenue TTM Q/Q Growth Statistics
High Average Low
184.2 %
58.76 %
-2.31 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 19
Overall # 201

Revenue TTM Y/Y Growth Statistics
High Average Low
184.2 %
58.76 %
-2.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 33
S&P 500 # 362




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CORT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CORT's Competitors
Revenue Growth for Corcept Therapeutics Inc's Suppliers
Revenue Growth for CORT's Customers

You may also want to know
CORT's Annual Growth Rates CORT's Profitability Ratios CORT's Asset Turnover Ratio CORT's Dividend Growth
CORT's Roe CORT's Valuation Ratios CORT's Financial Strength Ratios CORT's Dividend Payout Ratio
CORT's Roa CORT's Inventory Turnover Ratio CORT's Growth Rates CORT's Dividend Comparisons



Companies with similar Revenue increase for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Adma Biologics Inc 49.43%$ 49.427 millions
Insmed Inc48.27%$ 48.273 millions
Hims and Hers Health Inc 48.15%$ 48.151 millions
G1 Therapeutics Inc 45.10%$ 45.102 millions
Natera inc 43.20%$ 43.200 millions
Shockwave Medical Inc 41.36%$ 41.361 millions
Revance Therapeutics Inc 39.82%$ 39.819 millions
Evolus Inc 39.76%$ 39.759 millions
Ani Pharmaceuticals Inc39.71%$ 39.713 millions
Inspire Medical Systems inc 39.46%$ 39.459 millions
Insulet Corporation37.90%$ 37.896 millions
Foghorn Therapeutics Inc 37.88%$ 37.882 millions
Viemed Healthcare Inc 35.28%$ 35.275 millions
Kiniksa Pharmaceuticals ltd 34.76%$ 34.760 millions
Lantheus Holdings Inc 34.56%$ 34.557 millions
Xeris Biopharma Holdings Inc 33.93%$ 33.931 millions
Deciphera Pharmaceuticals Inc 32.88%$ 32.877 millions
Urogen Pharma Ltd 32.54%$ 32.539 millions
Anaptysbio Inc 32.27%$ 32.271 millions
Twist Bioscience Corporation31.81%$ 31.811 millions
Clearpoint Neuro Inc 31.62%$ 31.620 millions
Amicus Therapeutics inc 31.47%$ 31.466 millions
Corcept Therapeutics Inc31.39%$ 31.390 millions
Harmony Biosciences Holdings inc 31.30%$ 31.303 millions
Alnylam Pharmaceuticals Inc 31.25%$ 31.245 millions
Tarsus Pharmaceuticals Inc 30.76%$ 30.760 millions
Biofrontera Inc 30.41%$ 30.414 millions
Conmed Corporation30.37%$ 30.366 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com